NEW YORK, October 24, 2018 /PRNewswire/ --
According to a research report from Marijuana Business Daily, cannabis retail sales continued to increase year-over-year as
more states legalized cannabis products for both medical and recreational purposes. Sales in 2018 are projected to increase by
approximately 50% when compared to 2017. Sales value is also on track to reach USD 8 Billion - USD
10 Billion by the end of 2018. Additionally, the report specifies that by 2022, annual retail cannabis sales in the United States could exceed the USD 20 Billion mark, representing a 200%
surge from 2017. Legal cannabis markets are presently on the rise in major states such as California, Nevada, Colorado and
Washington, amongst others. Chemesis International Inc. (OTC: CADMF), AXIM® Biotechnologies,
Inc. (OTC: AXIM), Vitality Biopharma, Inc. (OTC: VBIO), Namaste Technologies Inc. (OTC: NXTTF), General Cannabis Corp. (OTC:
CANN)
North America is projected to be the biggest market for legal cannabis, as Canada's new laws, officially making
cannabis products legal, are expected to create a pioneering business environment. According to another report from Deloitte, the
total cannabis market in Canada is expected to generate up to USD 7.17
Billion in total sales in 2019, with up to USD 4.34 Billion coming from the legal channel.
Cannabis consumption through legal channels is expected to increase by up to 35%.
Chemesis International Inc. (OTC: CADMF) is also listed on the Canadian Securities Exchange under the ticker (CSE:
CSI). Earlier last week, the Company announced that, "its intention to enter the recreational and medical cannabis market in
Canada. The Company is reviewing possible joint ventures, agreements or acquisitions in
distribution, manufacturing, and product development spaces. Chemesis intends on leveraging its assets, brands, and management
expertise to gain market share in Canada. Chemesis is presently performing due diligence on
fully licensed and operational cannabis companies in Canada.
Canada has significant opportunity in both recreational and medical markets, with the
Canadian cannabis market expected to generate up to $7.17 billion CDN in 20191. The Company sees
major opportunities in Canada from high-quality manufacturing to brands that have developed a
strong presence in the market. Chemesis aims to introduce Canadian consumers its portfolio of brands which includes California
Sap, the Company's flagship brand. California Sap has been recognized in California since 2012,
with 25 gold rankings for best CO², best topical, best product, best concentrate, best cartridge, highest terpene and more.
'The Company is looking at multiple opportunities in Canada that will allow us to enter the
market and gain a strong presence with minimal regulatory hurdles,' said CEO, Edgar Montero.
'Chemesis is only evaluating businesses that have met regulatory and compliance standards. This allows the Company to enter into
the market with our assets, and expertise without unnecessary delay. The introduction of California Sap and our other brands will
allow Canadians the ability to purchase premium brands, that are extremely accomplished in California. As we continue to execute our business plan, Chemesis will look for acquisitions and
partnerships that bring growth and shareholder value.'"
AXIM® Biotechnologies, Inc. (OTCQB: AXIM) is an innovative biotechnology and pharmaceutical company focusing on
research, development and production of cannabinoid-based pharmaceutical and nutraceutical products. Recently, the Company
announced that the United States Patent and Trademark Office (USPTO) has issued a patent (US 10,092,538 B2) on a suppository
composition comprising cannabinoids developed by the Company. The Company's proprietary suppository composition is formulated for
easy absorption through the mucosal membrane, allowing for useful administration of cannabinoids in patients with pain, nausea,
vomiting, and other conditions preventing swallowing, or conditions wherein suppository administration is required. Most
significantly, AXIM plans to utilize this formulation for use in its clinical program that aims to treat gastrointestinal (GI)
conditions such as post-operative ileus and/or Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), and others. AXIM
is currently contemplating continuous clinical trials at the University of Wageningen in the
Netherlands for treatment of indications such as IBD and IBS with the Company's cannabinoid- based suppository product and
CanChew® Rx CBD (cannabidiol) functional, controlled release chewing gum.
Vitality Biopharma, Inc. (OTCQB: VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious
neurological and inflammatory disorders. Earlier this month, the Company announced the filing of national patent applications in
the United States and Canada that describe compounds discovered
to be effective in a drug screening model for neural repair. The discoveries included a compound that is known to have a positive
track record of safety in clinical trials and to provide pain relief through modulation of the vanilloid TRPV1
receptor. Cannabidiol (CBD), a non-intoxicating cannabinoid independently FDA-approved in pharmaceutical form for the
treatment of epilepsy, is also known to relieve pain through modulation of the TRPV1 receptor. As a result, Vitality has
made broad patent claims covering use of CBD and other TRPV1 agonists for myelin repair and for treatment of demyelinating
disorders.
Namaste Technologies Inc. (OTCQB: NXTTF) operates the largest global cannabis e-commerce platform with over 30 websites
in 20+ countries under various brands. Namaste's product offering through its subsidiaries includes vaporizers, glassware,
accessories, CBD products, and the Company will soon be selling medical cannabis through its wholly owned subsidiary CannMart in
the Canadian market. Recently, the Company announced that the Company's wholly-owned subsidiary, Cannmart Inc., has received its
Access to Cannabis for Medical Purposes Regulations ("ACMPR") medical cannabis "sales-only" license with no cultivation, which is
the first of its kind to be issued by Health Canada. The Sales License represents the most significant milestone in the history
of the Company and is the final component of its strategy for Cannmart to become Canada's
leading online platform for medical cannabis. Cannmart will operate as an online marketplace for medical cannabis sourced from
multiple Licensed Producers, which will offer patients a curated selection of medical cannabis strains in one location.
General Cannabis Corp. (OTCQX: CANN) is the comprehensive national resource for the highest-quality service providers
available to the regulated cannabis industry. As the legal cannabis industry grows throughout the
United States, the industry's leading service provider, General Cannabis Corp. recently announced it is expanding its
presence on the East Coast with the opening of a New York office. The New York office provides General Cannabis a strategic location to better serve existing East Coast clients
while also attracting new talent and partnerships as the cannabis market in the eastern U.S. continues to develop. Further,
the opening of the New York office provides a hub for current clients looking for East Coast
expansion opportunities. "Given our growing list of East Coast clients and the steps that states like Massachusetts and New Jersey have taken toward launching adult-use sales,
this is the ideal time for General Cannabis to further invest and establish itself in the region," said Michael Feinsod, Executive Chairman of the Board for General Cannabis. "The growth potential for the market in
this region is unparalleled. An East Coast office is perfectly suited to cater to this territory as General Cannabis continues to
expand its presence nationwide. We plan on expanding our security, operations and marketing segments aggressively throughout the
East Coast. In addition, we will be utilizing this office to expand and enhance our corporate, marketing and mergers and
acquisitions teams."
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our
unique financial newswire and media platform. For chemesis international inc. financial and corporate news dissemination,
FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either
a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof.
The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near
the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for
financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or
continue to post information about any companies the information contained herein is not intended to be used as the basis for
investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is
not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for
any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other
materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of
their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance,
and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound
by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com
constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment
strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is
solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives,
other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and
legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless
of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be
reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please
visit: http://www.financialbuzz.com .
For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: www.FinancialBuzz.com
SOURCE FinancialBuzz.com